Psychosocial support is vital to help those living with infertility to overcome treatment barriers, including stigmas, myths and taboos about IVF
BEIJING, May 9, 2026 /PRNewswire/ -- Diverse cultural or religious values across the Asia Pacific region mean that many people living with infertility face challenging family or societal attitudes when considering assisted reproductive treatment to achieve their dreams of parenthood. In many cases infertility generates personal shame and feelings of failure, as...
World’s First | Mabwell’s 9MW5211 Receives FDA Clearance for Clinical Trial Application
SHANGHAI, May 9, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Investigational New Drug (IND) application for 9MW5211, its independently developed novel antibody, has received clearance from the U.S. Food and Drug Administration (FDA) to conduct clinical studies for the treatment of inflammatory bowel disease (IBD). Clinical trial applications...
AAVnerGene Announces AAVone®2.1, a Next-Generation Single-Plasmid AAV Production Platform Achieving ~1e16 GC/L and >70% Full Capsids at Harvest
ROCKVILLE, Md., May 8, 2026 /PRNewswire/ -- USA -- AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® single-plasmid AAV production system, designed to improve AAV vector productivity, full-capsid yield, manufacturing efficiency, and cost effectiveness. AAVone®2.1 has achieved ~1x1016 genome copies (GC)/L of cell culture...
The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA
CHENGDU, China, May 8, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application") for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) was accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)...
What Sets Medtec China Apart from Other Medical Device Manufacturing Expos
SHANGHAI, May 8, 2026 /PRNewswire/ -- Building a successful medical device requires precise engineering, reliable materials, and a resilient supply chain. Finding the right partners to bring your vision to life is a major challenge. The Medtec China trade show solves this problem. As a leading medical device development expo, it stands as a premier gathering dedicated entirely to...
TOOTOO Self-Develops Ultra-Olaflur, Achieving a New Breakthrough in Super Cavity Protection for Children’s Toothpaste
Acid erosion resistance increased by 5 times, remineralization effect 1.7 times higher than previous generation Olaflur HANGZHOU, China, May 8, 2026 /PRNewswire/ -- Recently, Chinese children's age-specific wash and care brand TOOTOO (a brand under Hangzhou Daoyu Xingqing Biotechnology Co., Ltd.) has achieved a major scientific research breakthrough in the field of children's oral care. The company's three-year...
BioQ Debuts at in‑cosmetics Global, Showcasing China’s Advancing Strength in Ingredient Innovation
PARIS, May 8, 2026 /PRNewswire/ -- BioQ, the biotechnology affiliate of Chinese skincare brand GUYU, made its first appearance as a raw-material supplier at in-cosmetics Global, held April 14–16, 2026, in Paris. Widely regarded as the most prestigious stage for cosmetic ingredients, the event admits only companies with proven independent R&D and production capabilities — placing BioQ alongside established...
The 23rd World Congress on Breast Cancer and Breast Healthcare to Be Held in Tianjin
TIANJIN, China, May 8, 2026 /PRNewswire/ -- To further promote academic exchange and practical collaboration in the global field of breast health, and to advance the standardized prevention and treatment of breast cancer, the 23rd World Congress on Breast Cancer and Breast Healthcare will be held in Tianjin, China, from May 8–10, 2026. The congress is jointly organized by the...
Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, May 8, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New...
Rznomics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to ‘RZ-001’ for Hepatocellular Carcinoma
RMAT designation based on promising Phase 1b/2a clinical data, including safety profile and preliminary response rates, with trans-splicing ribozyme-based RNA editing platform SEOUL, South Korea, May 8, 2026 /PRNewswire/ -- Rznomics a biopharmaceutical company specializing in RNA-based gene therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation to RZ-001, its...
